Search our Database of Scientific Publications and Authors

I’m looking for a

    28063 results match your criteria Graft Versus Host Disease

    1 OF 562

    Late effects of blood and marrow transplantation.
    Haematologica 2017 Feb 23. Epub 2017 Feb 23.
    Fred Hutchinson Cancer Research Center, Seattle, USA.
    Hematopoietic cell transplantation is a curative treatment for a variety of hematologic diseases. Advances in transplantation technology have reduced early transplant-related mortality and expanded application of transplantation to older patients and to a wider variety of diseases. Management of late effects after transplantation is increasingly important for a growing number of long-term survivors that is estimated to be half a million worldwide. Read More

    Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection.
    Front Immunol 2017 8;8:41. Epub 2017 Feb 8.
    Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf , Hamburg , Germany.
    Besides donor T cells, natural killer (NK) cells are considered to have a major role in preventing relapse after allogeneic hematopoietic stem cell transplantation (HSCT). After T-cell-depleted haploidentical HSCT, a strong NK alloreactivity has been described. These effects have been attributed to killer-cell immunoglobulin-like receptors (KIR). Read More

    Multilayer amniotic membrane transplantation in severe ocular graft versus host disease.
    Eur J Ophthalmol 2001 Apr-Jun 2001;11(2):183-186
    Department of Ophthalmology, University Hospital "La Fe", Valencia - Spain.
    Purpose: To clarify the usefulness of multilayer amniotic membrane transplantation in an unusual case of calcareous corneal degeneration in a patient with graft-versus-host disease.

    Methods: A 20-year-old Caucasian woman had bilateral calcareous corneal degeneration of one year of evolution, secondary to graft-versus-host disease. Treatment for both eyes with topical steroids and antibiotic ointment was not successful. Read More

    Single CD28 stimulation induces stable and polyclonal expansion of human regulatory T cells.
    Sci Rep 2017 Feb 22;7:43003. Epub 2017 Feb 22.
    Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboud university medical center, Nijmegen, The Netherlands.
    CD4+FOXP3+ Treg are essential for immune tolerance. Phase-1 clinical trials of Treg-therapy to treat graft-versus-host-disease reported safety and potential therapeutic efficacy. Treg-based trials have started in organ-transplant patients. Read More

    Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression.
    J Transl Med 2017 Feb 21;15(1):40. Epub 2017 Feb 21.
    Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Via Olgettina 58, Milan, Italy.
    Background: Operational tolerance is an alternative to lifelong immunosuppression after transplantation. One strategy to achieve tolerance is by T regulatory cells. Safety and feasibility of a T regulatory type 1 (Tr1)-cell-based therapy to prevent graft versus host disease in patients with hematological malignancies has been already proven. Read More

    Ocular manifestations of chronic graft-versus-host disease in patients treated with extracorporeal photochemotherapy.
    Eur J Ophthalmol 2007 Nov-Dec;17:961-969
    Department of Ophthalmology and Neurosurgery, University of Siena, Siena - Italy.
    Purpose: Eye involvement has long been appreciated in patients with chronic graft versus host disease (cGVHD). In particular, ocular complications are frequent and can be potentially severe in patients with steroid-refractory cGVHD, and therefore necessitate close monitoring. This prospective study was designed to describe eye manifestations of cGVHD in a large series of patients monitoring them before and after 1 year of extracorporeal photochemotherapy (ECP). Read More

    The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.
    Br J Haematol 2017 Feb 21. Epub 2017 Feb 21.
    University Hospitals Birmingham NHS Trust, Birmingham, UK.
    Extracorporeal photopheresis (ECP) has been used for over 35 years in the treatment of erythrodermic cutaneous T-cell lymphoma (CTCL) and over 20 years for chronic and acute graft-versus-host disease (GvHD) and solid organ transplant rejection. ECP for CTCL and GvHD is available at specialised centres across the UK. The lack of prospective randomised trials in ECP led to the development of UK Consensus Statements for patient selection, treatment schedules, monitoring protocols and patient assessment criteria for ECP. Read More

    Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.
    Biol Blood Marrow Transplant 2017 Feb 17. Epub 2017 Feb 17.
    Hematology and Oncology Division, St. Lukes International Hospital.
    To evaluate the safety and efficacy of donor lymphocyte infusion (DLI), we retrospectively analyzed 414 recipients who received unrelated DLI (UDLI) for the treatment of relapsed hematological malignancy after unrelated bone marrow transplantation (BMT). UDLI was administered for acute myelogenous leukemia (n=184), myelodysplastic syndrome (n=69), acute lymphocytic leukemia (n=57), chronic myelogenous leukemia (CML, n=36), lymphoid neoplasms (n=38), adult T-cell leukemia/lymphoma (n=18), and multiple myeloma (n=12). Sixty-five patients (16%) were in cytogenetic/molecular relapse and 349 (84%) were in hematological relapse after BMT. Read More

    Marked in vivo Donor Treg Expansion via IL-2 and TL1A-Ig Stimulation Ameliorates GVHD but Preserves GVL in Recipients Post-HSCT.
    Biol Blood Marrow Transplant 2017 Feb 17. Epub 2017 Feb 17.
    Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL; Department of Microbiology & Immunology, University of Miami, Miller School of Medicine, Miami, FL; Department of Ophthalmology, University of Miami, Miller School of Medicine, Miami, FL. Electronic address:
    Regulatory T cells (Tregs) are critical for self-tolerance. While adoptive transfer of expanded Tregs limits graft-versus-host disease (GVHD) after hematopoietic cell transplantation (HCT), ex vivo generation of large numbers of functional Tregs remains difficult. Here, we demonstrate that in vivo targeting of the TNF superfamily receptor TNFRSF25 using the TL1A-Ig fusion protein, along with IL-2, resulted in transient but massive Treg expansion in donor mice, which peaked within days and was nontoxic. Read More

    Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.
    Ann Hematol 2017 Feb 18. Epub 2017 Feb 18.
    Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, 610 University Ave, Toronto, ON, M5G2M9, Canada.
    The CIBMTR chronic graft-versus-host disease (cGVHD) risk score can be refined and improved for better prognostic stratification. Three hundred and seven consecutive patients diagnosed with cGVHD by the NIH consensus criteria were retrospectively reviewed and had the CIBMTR risk score applied and analyzed. The CIBMTR risk score was successfully validated in our cohort (n = 307). Read More

    Paraneoplastic pemphigus associated with Castleman disease: Progression from mucous to mucocutaneous lesions with epitope-spreading phenomena.
    Br J Dermatol 2017 Feb 18. Epub 2017 Feb 18.
    Departments of Dermatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
    Paraneoplastic pemphigus (PNP) is a frequently fatal autoimmune blistering disease of the skin and mucous membranes.(1) PNP is commonly associated with malignant neoplasms or haematological disorders like Castleman disease (CD). The eruptions may resemble those seen in various other conditions such as lichen planus (LP), graft-versus-host disease, erythema multiforme (EM), bullous pemphigoid and pemphigus vulgaris (PV). Read More

    The Impact of Alemtuzumab Scheduling on Graft Versus Host Disease Following Unrelated Donor Fludarabine and Melphalan Allografts.
    Biol Blood Marrow Transplant 2017 Feb 14. Epub 2017 Feb 14.
    Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Northern Centre for Bone Marrow Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
    Alemtuzumab conditioning is highly effective at reducing the incidence of acute and chronic graft versus host disease (GVHD) in reduced intensity fludarabine and melphalan transplantation with ciclosporin monotherapy. Less frequent and lower dose scheduling may be used with sibling donors but an optimal regimen for matched unrelated donors has not been defined. In this retrospective observational study of 313 patients, the incidence and severity of GVHD was compared in patients receiving three different dose schedules: the standard 100mg regimen (20mg on day -7 to -3), 60mg (30mg day -4 and -2) or 50mg (10mg on day -7 to -3). Read More

    Human Gingiva-Derived Mesenchymal Stem Cells Inhibit Xeno-Graft-versus-Host Disease via CD39-CD73-Adenosine and IDO Signals.
    Front Immunol 2017 2;8:68. Epub 2017 Feb 2.
    Department of Clinical Immunology, Third Affiliated Hospital at Sun Yat-sen University, Guangzhou, China; Division of Rheumatology, Penn State Hershey College of Medicine, Hershey, PA, USA.
    Mesenchymal stem cells have the capacity to maintain immune homeostasis and prevent autoimmunity. We recently reported that human-derived gingival mesenchymal stem cells (GMSCs) have strong capacity to suppress immune responses and T cell-mediated collagen-induced arthritis in animals. However, it is unclear whether these cells can suppress human T cell-mediated diseases. Read More

    Noninvasive imaging of human immune responses in a human xenograft model of graft-versus-host disease.
    J Nucl Med 2017 Feb 16. Epub 2017 Feb 16.
    Whitehead Institute for Biomedical Research, United States.
    The immune system plays a crucial role in many diseases. Activation or suppression of immunity is often related to clinical outcome. Methods to explore the dynamics of immune responses are important to elucidate their role in conditions characterized by inflammation, such as infectious disease, cancer or auto-immunity. Read More

    The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality.
    Blood 2017 Feb 16. Epub 2017 Feb 16.
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
    Strategies to prevent active infection with certain double-stranded DNA (dsDNA) viruses after allogeneic hematopoietic cell transplantation (HCT) are limited by incomplete understanding of their epidemiology and clinical impact. We retrospectively tested weekly plasma samples from allogeneic HCT recipients at our center from 2007-2014. We used quantitative PCR to test for cytomegalovirus (CMV), BK polyomavirus (BKV), human herpesvirus 6B (HHV-6B), HHV-6A, adenovirus (AdV), and Epstein-Barr virus (EBV) between days 0-100 post-HCT. Read More

    Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Ann Rheum Dis 2017 Feb 16. Epub 2017 Feb 16.
    Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
    Objectives: To investigate the disease-modifying effects of phosphodiesterase 4 (PDE4) inhibition in preclinical models of systemic sclerosis (SSc).

    Methods: We studied the effects of PDE4 inhibition in a prevention and a treatment model of bleomycin-induced skin fibrosis, in the topoisomerase mouse model as well as in a model of sclerodermatous chronic graft-versus-host disease. To better understand the mode of action of PDE4 blockade in preclinical models of SSc, we investigated fibrosis-relevant mediators in fibroblasts and macrophages from healthy individuals and patients suffering from diffuse-cutaneous SSc on blockade of PDE4. Read More

    Risk factors of human herpesvirus 6 encephalitis/myelitis after allogeneic hematopoietic stem cell transplantation.
    Transpl Infect Dis 2017 Feb 16. Epub 2017 Feb 16.
    Department of Hematology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
    Background: Human herpesvirus 6 (HHV-6) encephalitis/myelitis is now a well-known complication after allogeneic stem cell transplantation (allo-HSCT), particularly after cord blood transplantation (CBT). In this study, we evaluated the risk factors of HHV-6 encephalitis/myelitis.

    Methods: We evaluated 253 patients who received allo-HSCT from 2007 to 2015 at our institute. Read More

    Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types.
    Oncotarget 2017 Feb 11. Epub 2017 Feb 11.
    Department of Hematology, Catholic Blood and Marrow Transplantation Center, Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
    Standard therapy for acute myeloid leukemia (AML) consists of hematopoietic cell transplantation (HCT) including autologous-HCT (AUTO) and allogeneic-HCT from a matched-sibling donor (MSD) or well-matched unrelated donor (WM-URD). When a conventional donor is not available, HCT from a partially-matched (PM)-URD or familial-mismatched donor (FMMD) is typically considered. We analyzed 561 patients with intermediate to poor-risk molecular cytogenetics who underwent transplant from 2002 to 2013 in their first remission. Read More

    Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis.
    Oncotarget 2017 Feb 11. Epub 2017 Feb 11.
    Bone Marrow Transplantation Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CHina.
    It remains controversial that the impacts of individual HLA locus mismatches on clinical outcomes of patients receiving unrelated-donor hematopoietic cell transplantation (HCT), as compared to HLA allele matched controls. We conducted a meta-analysis to address these issues. Four databases (PubMed, Embase, Web of Science and the Cochrane Library) were searched to select eligible studies. Read More

    A single-center analysis of chronic graft-versus-host disease-free, relapse-free survival after alternative donor stem cell transplantation in children with hematological malignancies.
    Int J Hematol 2017 Feb 15. Epub 2017 Feb 15.
    Department of Pediatrics, National Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka, 811-1395, Japan.
    We assessed the clinical outcomes of allogeneic hematopoietic stem cell transplantation (SCT) from alternative donors for pediatric patients with hematological malignancies, defining graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) as a composite endpoint. We also defined chronic GVHD-free, relapse-free survival (cGRFS) as survival without severe chronic GVHD, relapse, or death. The probabilities of 2-year disease-free survival from a human leukocyte antigen (HLA) matched unrelated donor (n = 57), related donor with HLA-1 antigen mismatch in the graft-versus-host direction (1Ag-GvH-MMRD, n = 28), and unrelated umbilical cord blood (n = 35) were 52. Read More


    Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning.
    Transpl Infect Dis 2017 Feb 15. Epub 2017 Feb 15.
    University of Calgary, Division of Hematology and Hematologic Malignancies, Calgary, AB, Canada.
    Background: Hemorrhagic cystitis (HC) is a complication of allogeneic stem cell transplantation (SCT), associated with factors such as BK polyomavirus reactivation, age, conditioning regimen, and presence of graft-versus-host disease (GVHD). The incidence and impact of HC in patients receiving fludarabine (Flu), busulfan (Bu), and anti-thymocyte globulin (ATG) conditioning is unknown.

    Methods: We conducted a case-control study of patients undergoing SCT at our center between January 1, 2003 and Dec 31, 2012, to determine the incidence of HC and its effect on patient outcomes including overall survival (OS), relapse, non-relapse mortality, GVHD, and healthcare resource use. Read More

    Quality of life of patients with graft-versus-host disease (GvHD) post-hematopoietic stem cell transplantation.
    Rev Esc Enferm USP 2016 Nov-Dec;50(6):953-960
    Universidade Federal do Paraná, Departamento de Enfermagem, Curitiba, PR, Brazil.
    Objective: Assessing the quality of life of adult patients with hematological cancer in the 100 days after transplantation of hematopoietic stem cells and verifying whether the variable graft-versus-host disease (GvHD) is predictive of worse results.

    Method: An observational correlational and quantitative study with 36 adult participants diagnosed with hematologic cancer who underwent hematopoietic stem cell transplantation from September 2013 to June 2015.

    Result: The mean age was 37 years, 52. Read More

    Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.
    Braz J Med Biol Res 2017 Feb 9;50(2):e5566. Epub 2017 Feb 9.
    Hematology-Oncology Division, C.H.U. Saint-Justine, University of Montreal, Montreal, QC, Canada.
    Acute graft-versus-host disease (aGVHD) and cytomegalovirus reactivation are important complications after allogeneic stem cell transplantation (alloHSCT). Here, we evaluated the impact of treatment with alemtuzumab on the occurrence of aGVHD, cytomegalovirus reactivation and survival after alloHSCT. This was a prospective cohort study conducted at the allo-HSCT unit of Hospital das Clínicas, Universidade Federal de Minas Gerais, Brazil, from January 2009 to December 2011. Read More

    Anti-Gal and anti-Neu5Gc responses in nonimmunosuppressed patients following treatment with rabbit anti-thymocyte polyclonal IgGs.
    Transplantation 2017 Feb 14. Epub 2017 Feb 14.
    1INSERM UMR 1064, Center for Research in Transplantation and Immunology, Nantes, France 2Société d'Accélération du Transfert de Technologies Ouest Valorisation, Rennes, France 3Xenothera, Nantes, France 4Biomarker Discovery Research, Immune Tolerance Network, Bethesda, MD, USA 5Institut de Transplantation-Urologie-Néphrologie (ITUN), Centre Hospitalier Universitaire de Nantes, France 6University of Nantes, France 7Clinical Trials Group, Immune Tolerance Network, San Francisco, CA, USA 8Division of Pediatric Endocrinology and Diabetes, University of California San Francisco, San Francisco, CA, USA.
    Background: Polyclonal anti-human thymocyte rabbit IgGs (anti-thymocyte globulin, ATG) are popular immunosuppressive drugs used to prevent or treat organ or bone-marrow allograft rejection, graft versus host disease, and autoimmune diseases. However, animal-derived glycoproteins are also strongly immunogenic and rabbit ATG induces serum sickness disease in almost all patients without additional immunosuppressive drugs, as seen in the START trial of ATG therapy in new-onset type 1 diabetes.

    Methods: Using ELISA, we analyzed serial sera from the START study to decipher the various anti-ATG specificities developed by the patients in this study: anti-total ATG, but also anti-galactose-α1-3-galactose (Gal) and anti-Neu5Gc antibodies, 2 xeno-carbohydrate epitopes present on rabbit IgG glycans and lacking in humans. Read More

    Delphi-based study and analysis of key risk factors for invasive fungal infection in haematological patients.
    Rev Esp Quimioter 2017 Feb 14. Epub 2017 Feb 14.
    Miguel Salavert, Unit of Infectious Diseases, Hospital Universitario y Politécnico La Fe Av. Fernando Abril Martorell 106, E-46026 Valencia, Spain.
    Objective: Mortality caused by invasive fungal infections due to filamentous fungi (IFI-FF) is high. Predisposing factors to IFI-FF are multiple and should be stratified. The objective of this study was to identify key risk factors for IFI-FF in onco-haematological patients in different clinical settings. Read More

    The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation.
    Oncoimmunology 2017 27;6(1):e1258506. Epub 2016 Dec 27.
    Department of Hematology and Stem Cell Transplant Program, Hôpital Maisonneuve-Rosemont, University of Montreal , Montreal, QC, Canada.
    The intestinal microbiota plays a key role in the pathogenesis of acute graft-versus-host disease (aGVHD). High-dose conditioning regimens given prior to allogeneic hematopoietic stem cell transplantation (aHSCT) modulate the composition of gut microbiota and damage the gut epithelial barrier, resulting in increased systemic inflammation. We assessed whether gut decontamination with antibiotics (ATB) prior to aHSCT influenced the frequency of aGVHD and mortality in 500 patients from two Canadian centers between 2005 and 2012. Read More

    Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells.
    JCI Insight 2017 Feb 9;2(3):e90088. Epub 2017 Feb 9.
    Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
    Rat and human CD4(+) and CD8(+) Tregs expressing low levels of CD45RC have strong immunoregulatory properties. We describe here that human CD45 isoforms are nonredundant and identify distinct subsets of cells. We show that CD45RC is not expressed by CD4(+) and CD8(+) Foxp3(+) Tregs, while CD45RA/RB/RO are. Read More

    An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
    JCI Insight 2017 Feb 9;2(3):e89798. Epub 2017 Feb 9.
    Tisch Cancer Institute, the Icahn School of Medicine at Mount Sinai.
    BACKGROUND. No laboratory test can predict the risk of nonrelapse mortality (NRM) or severe graft-versus-host disease (GVHD) after hematopoietic cellular transplantation (HCT) prior to the onset of GVHD symptoms. METHODS. Read More

    Antibiotic-Induced Depletion of Anti-Inflammatory Clostridia is Associated with the Development of GVHD in Pediatric Stem Cell Transplant Patients.
    Biol Blood Marrow Transplant 2017 Feb 9. Epub 2017 Feb 9.
    Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX; Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX; Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address:
    Adult stem cell transplantation (SCT) patients with graft-versus-host-disease (GVHD) exhibit significant disruptions in gut microbial communities. These changes are associated with higher overall mortality and appear to be driven by specific antibiotic therapies. It is unclear whether pediatric SCT patients who develop GVHD exhibit similar antibiotic-induced gut microbiota community changes. Read More

    Osteopontin attenuates acute gastrointestinal graft-versus-host disease by preventing apoptosis of intestinal epithelial cells.
    Biochem Biophys Res Commun 2017 Feb 9. Epub 2017 Feb 9.
    Department of Gastroenterology and Hepatology, Sapporo Medical University, School of Medicine, Minami 1-jo Nishi 17-chome, Chuo-ku, Sapporo, Hokkaido 060-8556, Japan; Department of Gastroenterology and Hepatology, Kyoto University, Graduate School of Medicine, 54 Shogoin, Kawahara-Cho, Sakyo-ku, Kyoto 606-8507, Japan. Electronic address:
    Background And Aims: Acute graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation, which often targets gastrointestinal (GI) tract. Osteopontin (OPN) plays an important physiological role in the efficient development of Th1 immune responses and cell survival by inhibiting apoptosis. The role of OPN in acute GI-GVHD is poorly understood. Read More

    Notch-Expanded Murine Hematopoietic Stem and Progenitor Cells Mitigate Death from Lethal Radiation and Convey Immune Tolerance in Mismatched Recipients.
    Stem Cells Transl Med 2017 Feb 13;6(2):566-575. Epub 2016 Sep 13.
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
    The hematopoietic syndrome of acute radiation syndrome (h-ARS) is characterized by severe bone marrow aplasia, resulting in a significant risk for bleeding, infections, and death. To date, clinical management of h-ARS is limited to supportive care dictated by the level of radiation exposure, with a high incidence of mortality in those exposed to high radiation doses. The ideal therapeutic agent would be an immediately available, easily distributable single-agent therapy capable of rapid in vivo hematopoietic reconstitution until recovery of autologous hematopoiesis occurs. Read More

    Concise Review: Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential Improvements.
    Stem Cells Transl Med 2017 Feb 13;6(2):539-565. Epub 2016 Sep 13.
    Division of Pulmonology, Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA.
    Mesenchymal stem cells (MSCs) represent a potentially revolutionary therapy for a wide variety of pediatric diseases, but the optimal cell-based therapeutics for such diversity have not yet been specified. The published clinical trials for pediatric pulmonary, cardiac, orthopedic, endocrine, neurologic, and hematologic diseases provide evidence that MSCs are indeed efficacious, but the significant heterogeneity in therapeutic approaches between studies raises new questions. The purpose of this review is to stimulate new preclinical and clinical trials to investigate these factors. Read More

    Successful umbilical cord blood hematopoietic stem cell transplantation in a patient with adult T-cell leukemia/lymphoma initially achieving complete remission with anti-CC chemokine receptor 4 antibody combined chemotherapy.
    Rinsho Ketsueki 2017 ;58(1):32-36
    Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine.
    A 62-year-old man with CHOP refractory adult T-cell leukemia/lymphoma (ATLL) received anti-CC chemokine receptor 4 antibody (mogamulizumab) combined with CHOP and achieved complete remission. At 71 days after the final administration of mogamulizumab, he received umbilical cord blood transplantation (CBT) using reduced intensity conditioning. Umbilical cord blood engraftment was confirmed on day16. Read More

    Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation.
    Biol Blood Marrow Transplant 2017 Feb 9. Epub 2017 Feb 9.
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington Medical Center, Seattle, Washington.
    The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) has been validated as a tool for evaluating the risk of treatment-related mortality (TRM) in HLA-matched sibling and matched unrelated donor bone marrow and peripheral blood stem cell transplantation patients. However, the role of the HCT-CI after cord blood transplantation (CBT) has not been fully investigated. In this analysis, we sought to evaluate the predictive value of the HCT-CI in patients undergoing reduced-intensity conditioning (RIC) CBT. Read More

    Decitabine Prior to Low-Dose Cytarabine-Based Chemotherapy Combined with HLA-Mismatched Stem Cell Micro-Transplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukaemia.
    Biol Blood Marrow Transplant 2017 Feb 8. Epub 2017 Feb 8.
    Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 300 Guangzhou Road, Nanjing 210029, China. Electronic address:
    The optimal treatment for elderly patients with acute myeloid leukaemia (AML) remains a great challenge. It is urgent and necessary to set up a more feasible, acceptable, accessible and safe treatment strategy for elderly patients. We conducted a prospective study of 23 elderly patients (median age 68 years; range from 60 to 87 years old) with newly diagnosed AML to evaluate the efficacy and toxicity of decitabine plus G-CSF priming, low-dose aclarubicin and cytarabine (DCAG) chemotherapy combined with human leukocyte antigen (HLA) mismatched stem cell micro-transplantation (SC-MST) without graft-versus-host disease (GVHD) prophylaxis. Read More

    Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease.
    Am J Pathol 2017 Feb 9. Epub 2017 Feb 9.
    Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
    Bone marrow transplantation (BMT) of B10.D2 mice into sublethally irradiated BALB/c mice across minor histocompatibility loci is a well-established animal model for human sclerodermatous chronic graft-versus-host disease (Scl-cGVHD) and systemic sclerosis (SSc). The p38 mitogen-activated protein kinase (MAPK) pathway is a key regulator of inflammation and cytokine production. Read More

    PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase.
    Blood 2017 Feb 10. Epub 2017 Feb 10.
    Department of Medicine, Queen Mary Hospital, Hong Kong.
    Natural killer (NK)/T-cell lymphomas failing L-asparaginse-regimens have no known salvage and are almost invariably fatal. Seven male NK/T-cell lymphoma patients (age: 49, 31-68, years) failing 2 (1-5) regimens (including L-asparaginase-regimens, and allogeneic hematopoietic stem cell transplantation, HSCT, in 2 cases), were treated with the anti-programmed-death-1 (PD1) antibody pembrolizumab. All patients responded, according to various clinical, radiologic (positron emission tomography), morphologic and molecular (circulating Epstein-Barr virus, EBV, DNA) criteria. Read More

    Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance.
    Transplantation 2017 Feb 10. Epub 2017 Feb 10.
    1Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States; 2Division of Organ Transplantation, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States; 3Department of Surgery, Tianjin Nankai Hospital, Tianjin, China; 4The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China; 5University of Louisville School of Medicine, Institute for Cellular Therapeutics, Louisville, KY, United States; 6Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States; 7Division of Gastroenterology & Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
    Background: Nonmyeloablative conditioning followed by donor bone marrow infusion (BMI) to induce tolerance has not been robustly tested in liver transplantation (LT) and may be unsafe at the time of LT. We hypothesized T cell depleted BMI is effective in inducing tolerance when delayed after LT, resulting in potentially safer future clinical applications.

    Methods: Nonimmunosuppressed syngeneic (Lewis to Lewis) and allogeneic (ACI to Lewis) rat LT transplants were initially performed as controls. Read More

    Mesenchymal Stromal Cell Therapy for Chronic Lung Allograft Dysfunction: Results of a First-in-Man Study.
    Stem Cells Transl Med 2017 Feb 1. Epub 2017 Feb 1.
    School of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
    Chronic lung transplant rejection (termed chronic lung allograft dysfunction [CLAD]) is the main impediment to long-term survival after lung transplantation. Bone marrow-derived mesenchymal stromal cells (MSCs) represent an attractive cell therapy in inflammatory diseases, including organ rejection, given their relative immune privilege and immunosuppressive and tolerogenic properties. Preclinical studies in models of obliterative bronchiolitis and human trials in graft versus host disease and renal transplantation suggest potential efficacy in CLAD. Read More

    HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
    J Transl Med 2017 Feb 10;15(1):28. Epub 2017 Feb 10.
    Department of Hematology, Shenzhen People's Hospital, 1017 Dongmen North Road, Shenzhen, 518020, China.
    Background: Acute graft-versus-host disease (aGVHD) remains a major obstacle against favorable clinical outcomes following allogeneic hematopoietic stem cell transplantation (allo-HSCT). T helper cells including Th17 play key roles in aGVHD pathogenesis. Donor regulatory T cell (Tregs) adoptive therapy reduces aGVHD without weakening graft-versus-leukemia effect (GVL) in both mouse and human, although the purification and ex vivo expansion of Tregs in clinical scenarios remain costly and technically demanding. Read More

    Acute kidney injury and mortality in hematopoietic stem cell transplantation: A single-center experience.
    Indian J Nephrol 2017 Jan-Feb;27(1):13-19
    Department of Community Medicine Christian Medical College and Hospital, Ludhiana, Punjab, India.
    Hematopoietic stem cell transplant (HSCT) is a life-saving procedure for patients with several malignant and nonmalignant hematological disorders. Acute kidney injury (AKI) is a common complication after HSCT. The aim of the study was to identify the incidence and outcomes of AKI associated with HSCT in our center. Read More

    Treatment of cutaneous and / or soft tissue manifestations of corticosteroids refractory chronic graft versus host disease (cGVHD) by a total nodal irradiation (TNI).
    Clin Transplant 2017 Feb 9. Epub 2017 Feb 9.
    Integrated Center of Oncology, ICO Paul Papin, Department of Radiotherapy, Angers.
    The management of corticosteroids refractory chronic graft versus host disease (cGVHD) remains controversial. Retrospective analysis of patients treated at the Integrated Center of Oncology by total nodal irradiation (TNI) was performed to evaluate its therapy potency. TNI delivers a dose of 1 Gy in a single session. Read More

    Lower incidence of acute GVHD is associated with the rapid recovery of CD4(+)CD25(+)CD45RA(+) regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based study.
    Oncoimmunology 2016 14;5(12):e1242546. Epub 2016 Oct 14.
    Peking University People's Hospital & Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, P.R. China.
    To investigate the effects of non-inherited maternal antigen (NIMA) on clinical outcomes and immune recovery, especially of regulatory T cells (Tregs), in patients who underwent unmanipulated haploidentical transplantation. A retrospective cohort (n = 57) and a prospective cohort (n = 88) were included. All patients received haploidentical allografts from sibling donors. Read More

    Haematopoietic stem cells: past, present and future.
    Cell Death Discov 2017 6;3:17002. Epub 2017 Feb 6.
    The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, Australia; Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.
    The discovery and characterisation of haematopoietic stem cells has required decades of research. The identification of adult bone marrow as a source of haematopoietic cells capable of protecting an organism from otherwise lethal irradiation led to the intense search for their identity and characteristics. Using functional assays along with evolving techniques for isolation of haematopoietic cells, haematopoietic stem cell populations were able to be enriched and their characteristics analysed. Read More

    Radiation-free, alternative donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.
    Blood 2017 Feb 8. Epub 2017 Feb 8.
    Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan-Kettering, NY, NY and Division of Pediatric Hematology-Oncology, New York Presbyterian Hospital - Weill Cornell, New York, NY, United States.
    Fanconi anemia (FA) is an inherited bone marrow failure syndrome characterized by chromosomal fragility, progressive marrow failure and cancer predisposition. Hematopoietic cell transplantation (HCT) is curative for FA-related marrow failure or leukemia, but both radiation exposure during transplant and graft-versus host disease (GVHD) may increase risk of later malignancies of the head and neck and anogenital area. In this study we tested a radiation-free conditioning regimen with a T-cell depleted graft to eliminate radiation exposure and minimize early as well as late toxicities of transplant. Read More

    The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters.
    Blood Rev 2017 Feb 2. Epub 2017 Feb 2.
    Division of Hematology and Blood and Marrow Transplantation, Department of Medicine, University of California, San Francisco, San Francisco, CA, United States; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, United States. Electronic address:
    Latent infection with human cytomegalovirus (CMV) is common. Functional immunity effectively contains such latent infections; however, CMV reactivation may cause significant complications in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT). In spite of the universal implementation of post-transplant screening for CMV viremia and the institution of pre-emptive antiviral management, CMV disease still occurs in a small portion of patients. Read More

    Transplantation of Donor-Origin Mouse Embryonic Stem Cell-Derived Thymic Epithelial Progenitors Prevents the Development of Chronic Graft-versus-Host Disease in Mice.
    Stem Cells Transl Med 2017 Jan 2;6(1):121-130. Epub 2016 Aug 2.
    Department of Allied Health Sciences, University of Connecticut, Storrs, Connecticut, USA.
    Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for many malignant and nonmalignant diseases. However, chronic graft-versus-host disease (cGVHD) remains a significant cause of late morbidity and mortality after allogeneic HSCT. cGVHD often manifests as autoimmune syndrome. Read More

    Allogeneic transplantation using CD34(+) selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia.
    Br J Haematol 2017 Feb 7. Epub 2017 Feb 7.
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
    Allogeneic haematopoietic stem cell transplantation is curative for severe aplastic anaemia (SAA) unresponsive to immunosuppressive therapy. To reduce chronic graft-versus-host disease (GVHD), which occurs more frequently after peripheral blood stem cell (PBSC) transplantation compared to bone-marrow transplantation (BMT), and to prevent graft rejection, we developed a novel partial T-cell depleted transplant that infuses high numbers of granulocyte colony-stimulating factor-mobilized CD34(+) selected PBSCs combined with a BMT-equivalent dose of non-mobilized donor T-cells. Fifteen patients with refractory SAA received cyclophosphamide, anti-thymocyte globulin and fludarabine conditioning, and were transplanted with a median 8 × 10(6) CD34(+)  cells/kg and 2 × 10(7) non-mobilized CD3(+) T-cells/kg from human leucocyte antigen-matched sibling donors. Read More

    1 OF 562